Spots Global Cancer Trial Database for Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Official Title: Pamiparib in Combination With Surufatinib in Patients With Platinum-resistant Ovarian Cancer Who Received Prior Poly (ADP-ribose) Polymerase (PARP) Inhibitors: a Multicenter, Single-arm, Phase Ib/II Trial

Study ID: NCT05494580

Conditions

Ovarian Cancer

Ovarian Carcinoma

Platinum-resistant Ovarian Cancer

Fallopian Tube Carcinosarcoma

Primary Peritoneal Cancer

Interventions

Pamiparib

Surufatinib

Study Description

Brief Summary: A number of studies suggest that the combination of PARP inhibitors and antiangiogenic agents produce synergistic activities. Pamiparib is a small molecule inhibitor selectivity for both PARP1 and PARP2. Surufatinib is a novel small-molecule inhibitor that simultaneously targets tumor angiogenesis (via Vascular Endothelial Growth Factor Receptor \[VEGFR\]1, VEGFR 2, VEGFR3 and Fibroblast Growth Factor Receptor 1 \[FGFR1\]) and immune evasion (via Colony Stimulating Factor 1 Receptor \[CSF1R\]). In this trial, we aimed to evaluate the efficacy, safety and tolerability of pamiparib in combination with surufatinib in patients with platinum-resistant ovarian cancer who received prior PARP inhibitors.

Detailed Description: